Psychosis reactivity to cannabis use in daily life: An experience sampling study

British Journal of Psychiatry

Volumn 196, Issue 6, 2010, Pages 447-453

  Henquet, Cécile ^a,b   Van Os, Jim ^a,c   Kuepper, Rebecca ^a   Delespaul, Philippe ^a,d   Smits, Maurice ^d   Campo, Joost À ^d   Myin Germeys, Inez ^a,e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Mondriaan Zorggroep   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Mondriaan Zorggroep ^*  (Netherlands)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELUSION; DISSOCIATION; DRUG EFFECT; DRUG USE; FEMALE; HALLUCINATION; HUMAN; MALE; MENTAL PATIENT; MOOD; PREDICTION; PSYCHOSIS; SAMPLING; SELF MEDICATION;

ADOLESCENT; ADULT; AFFECT; CASE-CONTROL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; HALLUCINATIONS; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; PSYCHOTIC DISORDERS; RISK FACTORS; SAMPLING STUDIES; YOUNG ADULT;

EID: 77952976236     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.109.072249     Document Type: Article

References (47)

1. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 2007; 8: 885-895 (Pubitemid 350006219)
2. Grech A, Van Os J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 2005; 20: 349-353 (Pubitemid 40978562)
3. Caspari D. Cannabis and schizophrenia: results of a follow-up study. Eur Arch Psychiatry Clin Neurosci 1999; 249: 45-49 (Pubitemid 29366776)
4. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-279
5. Compton MT, Furman AC, Kaslow NJ. Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res 2004; 71: 61-64
6. Spencer C, Castle D, Michie PT. Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull 2002; 28: 233-247 (Pubitemid 35462240)
7. Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005; 100: 612-618 (Pubitemid 40646286)
8. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005; 330: 11-15
9. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004; 99: 1333-1341
10. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991; 48: 764-770
11. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978; 35: 773-782 (Pubitemid 9064061)
12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276 (Pubitemid 18039085)
13. Myin-Germeys I, van Os J, Schwartz JE, Stone AA, Delespaul PA. Emotional reactivity to daily life stress in psychosis. Arch Gen Psychiatry 2001; 58: s1137-44.
14. Myin-Germeys I, Krabbendam L, Jolles J, Delespaul PA, van Os J. Are cognitive impairments associated with sensitivity to stress in schizophrenia? An experience sampling study. Am J Psychiatry 2002; 159: 443-449
15. Delespaul PAEG. Empirical studies in ESM reliability and validity. In Assessing Schizophrenia in Daily Life: The Experience Sampling Method. (ed. MW de Vries): 107. Maastricht University Press, 1995.
16. Myin-Germeys I, Marcelis M, Krabbendam L, Delespaul P, van Os J. Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry 2005; 58: 105-110 (Pubitemid 41008126)
17. Van Winkel R, Henquet C, Rosa A, Papiol S, Fananas L, De Hert M, et al. Evidence that the COMT(Val158Met) polymorphism moderates sensitivity to stress in psychosis: an experience-sampling study. Am J Med Genet B Neuropsychiatr Genet 2008; 147: 10-17
18. Delespaul P, deVries M, van Os J. Determinants of occurrence and recovery from hallucinations in daily life. Soc Psychiatry Psychiatr Epidemiol 2002; 37: 97-104.
19. Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156: 319-327 (Pubitemid 34857999)
20. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594-608. (Pubitemid 40409699)
21. Romme MA, Honig A, Noorthoorn EO, Escher AD. Coping with hearing voices: an emancipatory approach. Br J Psychiatry 1992; 161: 99-103.
22. Myin-Germeys I, Delespaul P, van Os J. Behavioural sensitization to daily life stress in psychosis. Psychol Med 2005; 35: 733-741 (Pubitemid 40716437)
23. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212-1213 (Pubitemid 35398785)
24. Thewissen V, Bentall RP, Lecomte T, van Os J, Myin-Germeys I. Fluctuations in self-esteem and paranoia in the context of daily life. J Abnorm Psychol 2008; 117: 143-153
25. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29: 2108-2114
26. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410: 588-592
27. Elphick MR, Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001; 356: 381-408.
28. Chevaleyre V, Takahashi KA, Castillo PE. Endocannabinoid-mediated synaptic plasticity in the CNS. Ann Rev Neurosci 2006; 29: 37-76.
29. Leweke FM, Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 2008; 13: 264-275
30. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 2004; 24: 4393-4400
31. Riegel AC, Lupica CR. Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area. J Neurosci 2004; 24: 11070-11078
32. Kapur S, Mizrahi R, Li M. From dopamine to salience to psychosis: linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2005; 79: 59-68.
33. Bentall RP, Kinderman P, Kaney S. The self, attributional processes and abnormal beliefs: towards a model of persecutory delusions. Behav Res Ther 1994; 32: 331-341
34. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009; 34: 759-766
35. Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM. Can recreational doses of THC produce significant dopamine release in the human striatum? NeuroImage 2009; 48: 186-190
36. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-environment interplay between cannabis and psychosis. Schizophr Bull 2008; 34: 1111-1121
37. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110-117 (Pubitemid 38186851)
38. Houston JE, Murphy J, Adamson G, Stringer M, Shevlin M. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. Schizophr Bull 2008; 34: 580-585
39. Harley M, Kelleher I, Clarke M, Lynch F, Arseneault L, Connor D, et al. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol Med 2009; 9: 1-8.
40. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene6environment interaction. Biol Psychiatry 2005; 57: 1117-1127
41. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, et al. An experimental study of catechol-O-methyltransferase Val(158)Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006; 31: 2748-2757
42. Jacobs N, Nicolson NA, Derom C, Delespaul P, van Os J, Myin-Germeys I. Electronic monitoring of salivary cortisol sampling compliance in daily life. Life Sci 2005; 76: 2431-2443 (Pubitemid 40341960)
43. Di Forti M, Morgan C, Dazzan P, Pariante C, Mondelli V, Marques TR, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009; 195: 488-491
44. Morgan CJA, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008; 192: 306-307
45. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton- Brown T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010; 35: 764-774
46. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, et al. Blunted psychotomimetic and amnestic effects of delta-9- tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008; 33: 2505-2516
47. Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001; 158: 1706-1713 (Pubitemid 32923666)